EPS: As of FY2025 Q2, the actual value is USD -0.01.<h3>Operating Expenses</h3><ul><li>Research and Development: For the three months ended June 30, 2025, the company recorded $102,500 in clinical trial costs. For the six months ended June 30, 2025, the company recorded $452,000 in development expenses, compared to $27,000 for the same period in 2024.</li><li>General and Administrative: Total general and administrative expenses were $121,579 for the three months ended June 30, 2025, and $287,220 for the six months ended June 30, 2025, compared to $609,322 and $1,361,551 for the same periods in 2024, respectively.</li></ul><h3>Other Expenses</h3><ul><li>Interest Expense: For the three months ended June 30, 2025, interest expense was $45,377, including $15,265 to affiliates. For the six months ended June 30, 2025, interest expense was $77,267, including $15,998 to affiliates.</li><li>Derivative Liability: The change in fair value of the derivative liability reduced it by $307,402 for the three months ended June 30, 2025, but increased it by $497,350 for the six months ended June 30, 2025.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $248,010 for the six months ended June 30, 2025, compared to - $179,832 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $15,177 for the six months ended June 30, 2025, compared to - $5,302 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $261,177 for the six months ended June 30, 2025, compared to $172,570 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to raise $3,700,000 to fund operations and continue product development over the next 15 months. The focus is on developing and commercializing therapeutic molecules for stroke, with BXT-25 as a key product candidate.</li><li>Non-Core Business: The company is exploring financing alternatives, including a potential $2 million private placement offering under Regulation D in spring 2025, to support regulatory approval activities.</li></ul>

Bioxytran, Inc. | 10-Q: FY2025 Q2 EPS: USD -0.01